Shares of Aquestive Therapeutics surged 9.3% in pre-market trading to $4.63, as investors renewed their focus on two financing deals designed to bankroll the company's flagship product — a tiny dissolving film that could replace the traditional epinephrine auto-injector for life-threatening allergic reactions.
$160 Million in Capital, But Every Dollar Hinges on FDA Approval
Aquestive secured a $75 million strategic funding agreement with RTW Investments, conditional on FDA approval of its allergy rescue film and other conditions.
Separately, the company priced an $85 million stock offering — selling 21.25 million shares at $4.00 each.
Proceeds are earmarked primarily to launch and commercialize the product. That's $160 million in total firepower, but the RTW tranche only unlocks after the FDA says yes — meaning the company is spending real money now on a bet that regulators will cooperate.
An FDA Rejection Already Stung Once This Year
The FDA issued a Complete Response Letter on January 30, 2026 — essentially a formal rejection — flagging deficiencies in the drug's packaging and how patients would use it.
Shares cratered 37% on that news.
Aquestive completed a follow-up meeting with the FDA in March and reaffirmed plans to resubmit its application in Q3 2026.
Crucially, the FDA did not question the drug's core clinical data or manufacturing quality. The issues appear fixable, but a second rejection would be devastating for a company burning cash at this rate.
The Balance Sheet Buys Time, Not Certainty
Aquestive holds $110.7 million in cash against $43.6 million in debt.
In May, it also refinanced existing debt into a new $150 million facility with Oaktree Capital, pushing principal repayments to zero over the next three years.
Yet the company posted $50.3 million in trailing revenue against $68.9 million in losses.
Free cash flow runs at roughly negative $44 million annually. The math is clear: without approval and a successful launch, cash runs out well before 2028.
Dilution Is Real, and Shorts Are Watching
The share count now sits at 125.5 million, up 23% in one year — meaning existing shareholders own a smaller slice of the same uncertain pie. Short interest stands at 12.15% of outstanding shares , a sign that plenty of professional traders are betting this story doesn't end well. At $4.63, the market is pricing in meaningful odds of approval — but investors are buying a lottery ticket, not a sure thing.